Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma
2007

Using P501s to Detect Prostate Cancer

Sample size: 224 publication Evidence: moderate

Author Information

Author(s): Yin Ming, Dhir Rajiv, Parwani Anil V

Primary Institution: University of Pittsburgh Medical Center

Hypothesis

The study aims to evaluate the expression of P501s in metastatic prostatic adenocarcinoma and compare it with PSA.

Conclusion

P501s is a specific marker for prostatic cells and improves the detection of metastatic prostate cancer when used alongside PSA.

Supporting Evidence

  • P501s was expressed in all benign glands and malignant acini.
  • No staining was observed in non-prostatic tissues.
  • Simultaneous stains with P501s and PSA improved detection rates.

Takeaway

P501s helps doctors find prostate cancer better, especially when PSA tests don't work well.

Methodology

Immunohistochemical stains with anti-P501s antibodies were performed on tissue microarray specimens from various prostate-related tissues.

Limitations

The study did not provide Gleason scores for the metastatic lesions, which may affect the interpretation of results.

Participant Demographics

The study included various prostate tissue types, including normal, benign, and malignant samples.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1746-1596-2-41

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication